Skip to main content

ADvanced nanocomposite MAterIals fOr in situ treatment and ultRAsound-mediated management of osteoarthritis

Objective

Osteoarthritis (OA) is a major burden that affects ~ 40 million of EU citizens, with enormous direct and indirect costs for the European healthcare systems, quantified in ~ 50.4 billion euros per year. This disease involves the degeneration of cartilage and other joint structures and is one of the most common causes of pain and disability in middle-aged and elderly people. ADMAIORA aims in the long-term at increasing the healthy and active lifespan of people affected by OA, by considerably slowing down or even stopping the degeneration process, thus delaying or avoiding surgical interventions for total joint replacement. Within the project time-frame the target is to achieve a 60% reduction of degeneration in OA animal models treated with the ADMAIORA technologies, with respect to control (untreated) ones, after 4 weeks, and a 90% reduction after 3 months. To achieve this ambitious objective the Consortium will evolve and merge technologies that already showed a high potential as experimental proof of concepts (TRL = 3) and will bring them at a preclinical level (TRL = 5). The ADMAIORA Consortium will develop biosynthetic hydrogels embedded with carbon-based nanomaterials, conferring higher mechanical and lubrication properties, and piezoelectric nanoparticles enabling responsivity to remote wireless ultrasound waves. Stem cells derived from autologous adipose tissue, which already demonstrated anti-inflammatory and regenerative properties, will be entrapped in the hydrogels. Materials and cells will be delivered in situ through an innovative handheld 3D bioprinter, embedded in an arthroscopic tool. A custom brace will be designed and equipped with ultrasound probes for both monitoring the joint status and stimulating the implanted piezoelectric nanobiomaterial. A dedicated App will allow a direct connection between patient and physician in an Internet of Things framework. Overall, ADMAIORA will target a ground-breaking paradigm that may revolutionize OA treatment.

Call for proposal

H2020-NMBP-TR-IND-2018
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO S ANNA
Address
Piazza Martiri Della Liberta 33
56127 Pisa
Italy
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 071 500

Participants (7)

BAR ILAN UNIVERSITY
Israel
EU contribution
€ 524 800
Address
Bar Ilan University Campus
52900 Ramat Gan
Activity type
Higher or Secondary Education Establishments
ISTITUTO ORTOPEDICO RIZZOLI
Italy
EU contribution
€ 1 112 500
Address
Via Di Barbiano 1/10
40136 Bologna
Activity type
Research Organisations
REGENTIS BIOMATERIALS LTD

Participation ended

Israel
EU contribution
€ 609 250
Address
Ha Ilan Street 2 Northern Industrial Zone
30600 Or Akiva
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
IMAGE GUIDED THERAPY SA
France
EU contribution
€ 670 500
Address
Allee Du Doyen Georges Brus 2 Scientifique Unitec 1
33600 Pessac
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PLASMACHEM PRODUKTIONS- UND HANDEL GMBH
Germany
EU contribution
€ 325 625
Address
Schwarzschildstrasse 10
12489 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
VIMEX SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
Poland
EU contribution
€ 506 375
Address
Torunska 27
44 122 Gliwice
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
HITECH DEVELOPMENT WIRELESS SWEDENAB
Sweden
EU contribution
€ 576 930
Address
Farogatan 33 Vpl 44
16451 Kista
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)